Across the medtech industry, some of the largest players have shed entire divisions as they seek to narrow their focus on their core businesses. These moves range from J&J spinning out its Kenvue consumer operations, to Baxter selling off its multibillion-dollar kidney care unit, to GE HealthCare keeping the name of its conglomerate parent as it became an independent company. During this panel, we’ll explore the forces driving these divestitures and their effects on competition, branding, M&A and the broader market landscape—as well as whether elder firms have found success with smaller portfolios, and if the newcomers have found their footing.
